Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery · 2025
[Endovascular aortic aneurysm repair under the guidance of gas angiography].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zatevakhin I I, Tsitsiashvili M Sh, Shipovsky V N, Frantsevich A M, Ibragimov S A
Аннотация
OBJECTIVE: To develop a safe technique of visualizing the abdominal aorta during endovascular aortic aneurysm repair (EVAR) using an alternative contrast agent - medical carbon dioxide (CO2).
PATIENTS AND METHODS: In 2023-2024, a total of nine 58-to-74-year-old male patients underwent EVAR under the guidance of medical carbon dioxide (CO2). Six patients were preoperatively diagnosed as having chronic kidney disease (CKD).
RESULTS: The technical success of EVAR using medical carbon dioxide (CO2) alone was achieved in 7 patients (77.8%). In 2 patients (22.3%), due to insufficient imaging, we were forced to use combined angiography (CO2 + iohexol). The average amount of injected carbon dioxide in the first group per patient was 350±50 cm3, with the average amount of injected iohexol in the second group of patients equaling 20±5 ml. None of the patients in both groups with CKD required hemodialysis or additional hydration therapy. The parameters of renal markers before and after carboxygraphy did not change.
CONCLUSION: Medical carbon dioxide (CO2) can be safely and effectively used as a contrast agent during EVAR in patients with CKD.
PATIENTS AND METHODS: In 2023-2024, a total of nine 58-to-74-year-old male patients underwent EVAR under the guidance of medical carbon dioxide (CO2). Six patients were preoperatively diagnosed as having chronic kidney disease (CKD).
RESULTS: The technical success of EVAR using medical carbon dioxide (CO2) alone was achieved in 7 patients (77.8%). In 2 patients (22.3%), due to insufficient imaging, we were forced to use combined angiography (CO2 + iohexol). The average amount of injected carbon dioxide in the first group per patient was 350±50 cm3, with the average amount of injected iohexol in the second group of patients equaling 20±5 ml. None of the patients in both groups with CKD required hemodialysis or additional hydration therapy. The parameters of renal markers before and after carboxygraphy did not change.
CONCLUSION: Medical carbon dioxide (CO2) can be safely and effectively used as a contrast agent during EVAR in patients with CKD.